Products
Tanezumab Biosimilar Monoclonal Antibody (NGF) for Research
Pre-Made Tanezumab biosimilar, Whole mAb, Anti-NGFB/NGF Antibody: Anti-HSAN5 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Tanezumab (INN, codenamed RN624) is a monoclonal antibody against nerve growth factor as a treatment for pain. Tanezumab was discovered and developed by Rinat Neuroscience and was acquired by Pfizer in 2006.
Order Information
| Catalog No. | Package | List Price(In USD) | Discount off | Discount Price |
|---|---|---|---|---|
| GMP-Bios-ab-549-1mg | 1mg | 3090 |
Size： 1mg | 10mg | 100mg
Product Details
| Products Name (INN Index) | Pre-Made Tanezumab biosimilar, Whole mAb, Anti-NGFB/NGF Antibody: Anti-HSAN5 therapeutic antibody |
| INN Name | Tanezumab |
| Target | NGF |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG2 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Preregistration |
| Est. Status | Active |
| 100% SI Structure | 4edw:HL |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2008 |
| Year Recommended | 2009 |
| Companies | Rinat Neuroscience;Pfizer |
| Conditions Approved | na |
| Conditions Active | Back pain;Cancer pain;Musculoskeletal pain |
| Conditions Discontinued | Diabetic neuropathies;Postherpetic neuralgia |
| Development Tech | na |
About target - NGFB
1. Protein Beta-nerve growth factor
2. Gene NGFB
3. Organism Homo sapiens (Human)
Function
Nerve growth factor is important for the development and maintenance of the sympathetic and sensory nervous systems (PubMed:14976160, PubMed:20978020).
Extracellular ligand for the NTRK1 and NGFR receptors, activates cellular signaling cascades to regulate neuronal proliferation, differentiation and survival (PubMed:20978020) (Probable).
The immature NGF precursor (proNGF) functions as ligand for the heterodimeric receptor formed by SORCS2 and NGFR, and activates cellular signaling cascades that lead to inactivation of RAC1 and/or RAC2, reorganization of the actin cytoskeleton and neuronal growth cone collapse. In contrast to mature NGF, the precursor form (proNGF) promotes neuronal apoptosis (in vitro) (By similarity).
Inhibits metalloproteinase-dependent proteolysis of platelet glycoprotein VI (PubMed:20164177).
Binds lysophosphatidylinositol and lysophosphatidylserine between the two chains of the homodimer. The lipid-bound form promotes histamine relase from mast cells, contrary to the lipid-free form (By similarity).
